mirabella 0,10+0,02 mg filmovertrukne tabletter
exeltis healthcare s.l - ethinylestradiol, levonorgestrel - filmovertrukne tabletter - 0,10+0,02 mg
mirabella 28 0,10+0,02 mg filmovertrukne tabletter
exeltis healthcare s.l - ethinylestradiol, levonorgestrel - filmovertrukne tabletter - 0,10+0,02 mg
rigevidon 0,15+0,03 mg overtrukne tabletter
gedeon richter plc. - ethinylestradiol, levonorgestrel - overtrukne tabletter - 0,15+0,03 mg
vellena 75+20 mikrogram overtrukne tabletter
actavis group ptc ehf. - ethinylestradiol, gestoden - overtrukne tabletter - 75+20 mikrogram
vellena 75+30 mikrogram overtrukne tabletter
actavis group ptc ehf. - ethinylestradiol, gestoden - overtrukne tabletter - 75+30 mikrogram
denise 150+30 mikrogram tabletter
2care4 aps - desogestrel, ethinylestradiol - tabletter - 150+30 mikrogram
alunbrig
takeda pharma a/s - brigatinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
natriumoxybat "kalceks" 500 mg/ml oral opløsning
kalceks as - natriumoxybat - oral opløsning - 500 mg/ml
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
levonorgestrel/ethinylestradiol "2care4" 0,10+0,02 mg filmovertrukne tabletter
2care4 aps - ethinylestradiol, levonorgestrel - filmovertrukne tabletter - 0,10+0,02 mg